Asprin And Extended-Release Dipyridamole

Asprin And Extended-Release Dipyridamole · ASPIRIN 25 mg/1; DIPYRIDAMOLE 200 mg/1 · Capsule · Oral · Glenmark Pharmaceuticals Inc., USA

NDC 68462-0405-60 · 60 CAPSULE in 1 BOTTLE · ANDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. The price has held steady around $0.5592 per unit over the past year. One of its named manufacturing plants, Glenmark Pharmaceuticals Limited, failed FDA inspectionwithin the last two years — the agency’s most serious outcome. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built

Data sources

CMS NADAC (pharmacy acquisition, weekly)
CMS Part B ASP quarterly payment limits
CMS Maximum Fair Prices (IRA negotiated, NDC-level)
Medicare Part D Spending by Drug (data.cms.gov, name-matched)
VA FSS / Big4 federal contract prices (va.gov, twice monthly)
ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
California SB-17 WAC filings (list price, per package)

Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Pharmacies pay (NADAC)$0.5592per EAinvoice-surveyed acquisition cost · Aug 19, 2026
Part D point of sale (median)$1.27per unitnegotiated price across 4,538 plans — before rebates · Apr 1, 2026
Medicaid generic ceiling (FUL)$0.5592per CAPweighted avg manufacturer price $0.3165 · Aug 1, 2026100% of what pharmacies pay — higher than 10% of drugs with this benchmark

Medicare Part D

All Part D pricing →

ⓘ How this was built

Data sources

CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)

Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ

$1.27per unit

middle half $0.8582–$1.82 · 4,538 plans · Apr 1, 2026

Est. net of rebatesⓘ

≈ $1.27

generic — rebates are minimal, so net ≈ gross

Coverage & restrictions

83%of plans cover it

tier 4 · prior auth 0% · step therapy 0% · qty limit 46%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

78 price points · per EA · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

#30 count

$16.78

#90 count

$50.33

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2024)

$7,712

128 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

30● Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

1 active manufacturer+30

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for asprin and extended-release dipyridamole (oral solid) in the next 90 days

OAI inspection at a producing facility (24 months)

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Glenmark Pharmaceuticals LimitedOAIIndia
analysis · manufacture

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application: ANDA210318
TE code: AB
Approval date: May 24, 2019
Patents / exclusivity: None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

Class III · OngoingJun 29, 2022
Glenmark Pharmaceuticals Inc., USA — Failed Tablet/Capsule Specification : Capsule breakage

Manufacturers of Asprin And Extended-Release Dipyridamole (Capsule)

Labeler	Strength	First seen	Last seen
Glenmark Pharmaceuticals Inc., USA	ASPIRIN 25 mg/1; DIPYRIDAMOLE 200 mg/1	Jul 15, 2026	Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Asprin And Extended-Release Dipyridamole — NDC 68462-0405-60," retrieved September 3, 2026, https://drugdashboards.com/drug/68462040560.

Free to cite with attribution — see how the data is put together.